Published in J Natl Cancer Inst on March 03, 1993
Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol (2007) 2.15
Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci U S A (2012) 1.72
Multiple functions of the 37/67-kd laminin receptor make it a suitable target for novel cancer gene therapy. Mol Ther (2009) 1.03
La enhances IRES-mediated translation of laminin B1 during malignant epithelial to mesenchymal transition. Nucleic Acids Res (2011) 1.03
Prognosis based on primary breast carcinoma instead of pathological nodal status. Br J Cancer (1994) 0.93
Cancer and metastasis: prevention and treatment by green tea. Cancer Metastasis Rev (2010) 0.93
Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor interaction. Nat Chem Biol (2013) 0.92
Regulation of extracellular matrix remodeling and cell fate determination by matrix metalloproteinase stromelysin-3 during thyroid hormone-dependent post-embryonic development. Pharmacol Ther (2007) 0.92
Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features. Br J Cancer (1994) 0.90
Vitamin A enhances antitumor effect of a green tea polyphenol on melanoma by upregulating the polyphenol sensing molecule 67-kDa laminin receptor. PLoS One (2010) 0.88
Structure-guided identification of a laminin binding site on the laminin receptor precursor. J Mol Biol (2010) 0.87
Looking into laminin receptor: critical discussion regarding the non-integrin 37/67-kDa laminin receptor/RPSA protein. Biol Rev Camb Philos Soc (2015) 0.86
Green tea polyphenol EGCG sensing motif on the 67-kDa laminin receptor. PLoS One (2012) 0.84
Nuclear and cytoplasmic free calcium level changes induced by elastin peptides in human endothelial cells. Proc Natl Acad Sci U S A (1998) 0.83
The laminin receptor modulates granulocyte-macrophage colony-stimulating factor receptor complex formation and modulates its signaling. Proc Natl Acad Sci U S A (2003) 0.83
Expression of 32/67-kDa laminin receptor in laminin adhesion-selected human colon cancer cell lines. Br J Cancer (1998) 0.81
Mutational analysis of the cleavage of the cancer-associated laminin receptor by stromelysin-3 reveals the contribution of flanking sequences to site recognition and cleavage efficiency. Int J Mol Med (2009) 0.81
Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma. Clin Exp Metastasis (2003) 0.79
Genetic identification of antigens exposed in damaged endothelial cells as laminin-binding proteins. Clin Exp Immunol (1998) 0.78
Laminin receptor 37/67LR regulates adhesion and proliferation of normal human intestinal epithelial cells. PLoS One (2013) 0.78
A role for extracellular matrix binding receptors in regulating hematopoietic growth factor signaling. Proc Natl Acad Sci U S A (2003) 0.78
Knockdown of LRP/LR Induces Apoptosis in Breast and Oesophageal Cancer Cells. PLoS One (2015) 0.77
Comprehensive proteomic analysis of nonintegrin laminin receptor interacting proteins. J Proteome Res (2012) 0.77
Eukaryote-specific extensions in ribosomal proteins of the small subunit: Structure and function. Translation (Austin) (2015) 0.75
Expression of high-affinity 67-kDa laminin receptors in primary breast cancers and metachronous metastatic lesions or contralateral cancers. Br J Cancer (1997) 0.75
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet (1996) 3.78
Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med (1993) 3.54
P53 expression in breast cancer. Int J Cancer (1988) 3.51
Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med (1977) 3.45
Updated Kiel classification for lymphomas. Lancet (1988) 3.25
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer (1982) 2.71
Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet (1991) 2.58
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57
Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst (1995) 2.52
Stage I melanoma of the limbs: assessment of prognosis by levels of invasion and maximum thickness. Tumori (1978) 2.46
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol (2008) 2.37
Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A (1997) 2.36
Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest (1996) 2.31
Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer (1995) 2.30
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer (1995) 2.28
Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg (2000) 2.27
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst (1990) 2.25
Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol (1998) 2.23
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med (1988) 2.15
The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst (1994) 2.06
Comparison of Halsted mastectomy with quadrantectomy, axillary dissection, and radiotherapy in early breast cancer: long-term results. Eur J Cancer Clin Oncol (1986) 2.05
Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer (1987) 1.99
Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res (1998) 1.96
Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol (2000) 1.94
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93
Surgical treatment of phyllodes tumors of the breast. Cancer (1989) 1.89
Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol (1994) 1.80
Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. Eur J Cancer (1998) 1.68
Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res (1991) 1.65
Results of adjuvant interferon study in WHO melanoma programme. Lancet (1994) 1.62
Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res (1983) 1.60
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol (1996) 1.55
Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol (1997) 1.55
Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer (1988) 1.55
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat (1999) 1.54
Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg (1991) 1.52
Adequacy of margins of resection in gastrectomy for cancer. Ann Surg (1982) 1.52
Laparoscopy and laparotomy combined with bone marrow biopsy in staging Hodgkin's disease. Br Med J (1975) 1.52
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Intercomparison on the usage of computational codes in radiation dosimetry. Radiat Prot Dosimetry (2004) 1.51
Primary non-Hodgkin's lymphomas of the female breast. Cancer (1992) 1.50
Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg (1983) 1.50
Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol (1978) 1.49
Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Società Italiana di Ecografia Cardiovascolare) multicentre study. Eur Heart J (2001) 1.48
Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer (1987) 1.48
Expression of the monomeric 67-kd laminin-binding protein in human lymphomas as defined by MLuC5 monoclonal antibody and paraffin section immunohistochemistry. Hum Pathol (1995) 1.45
Total rectal resection and complete mesorectum excision followed by coloendoanal anastomosis as the optimal treatment for low rectal cancer: the experience of the National Cancer Institute of Milano. Ann Surg Oncol (2000) 1.45
Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer (1996) 1.43
Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol (1990) 1.40
Distinct morphophenotypic features of chronic B-cell leukaemias identified with CD1c and CD23 antibodies. Eur J Haematol (1991) 1.39
Acral-lentiginous naevus of plantar skin. Histopathology (1995) 1.39
Viral particles in cervical condylomatous lesions. Tumori (1978) 1.36
Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer (1994) 1.34
Formation of the 67-kDa laminin receptor by acylation of the precursor. J Cell Biochem (1998) 1.34
The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol (1998) 1.33